APA (7th ed.) Citation

Abdullah, A., Alaiya, A., Al-Mohanna, F., Attwa, M. W., AlAsmari, A. F., Bakheet, S. A., & Korashy, H. M. (2022). Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy.

Chicago Style (17th ed.) Citation

Abdullah, Al-Dhfyan, Ayodele Alaiya, Falah Al-Mohanna, Mohamed W. Attwa, Abdullah F. AlAsmari, Saleh A. Bakheet, and Hesham M. Korashy. Crosstalk Between Aryl Hydrocarbon Receptor (AhR) and BCL-2 Pathways Suggests the Use of AhR Antagonist to Maintain Normal Differentiation State of Mammary Epithelial Cells During BCL-2 Inhibition Therapy. 2022.

MLA (9th ed.) Citation

Abdullah, Al-Dhfyan, et al. Crosstalk Between Aryl Hydrocarbon Receptor (AhR) and BCL-2 Pathways Suggests the Use of AhR Antagonist to Maintain Normal Differentiation State of Mammary Epithelial Cells During BCL-2 Inhibition Therapy. 2022.